VANECK BIOTECH ETF (BBH) Stock News

VanEck Announces Year-End Distributions for VanEck Equity ETFs

VanEck Announces Year-End Distributions for VanEck Equity ETFs

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone. 

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

VanEck Launches Robotics ETF (IBOT)

3 Best Funds for Aggressive Investors

These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year.

Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money

With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in.

Progenity Is Unlikely to Live Up to Its IPO Hype

Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?

Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone

After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy.

2 Winning Biotech Stocks to Buy for the Fourth Quarter

The biotech industry is expected to remain in focus as the coronavirus is far from gone and an aging population will require even more healthcare. Given the industry’s solid growth potential, Harmony Biosciences (HRMY) and Dynavax Technologies (DVAX), which have performed well so far, could be solid bets for the fourth quarter.

3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170%

The rapid spread of the COVID-19 Delta variant is fostering renewed investor interest in the biotech industry. Also, with the increasing demand for treatments for other critical diseases, the industry is expected to continue on a growth trajectory. So, we think it could be wise to bet on biotech stocks ASLAN Pharmaceuticals (ASLN), Aquestive Therapeutics (AQST), and Aravive (ARAV). They have promising portfolios of products and Wall Street analysts see tremendous upside potential for these stocks in the near term. Read on.

4 Biotech Stocks Wall Street Analysts Predict Will Gain More Than 60%

The biotech industry has witnessed solid growth over the past year, in large measure attributable to the demand for drugs to fight COVID-19, among other diseases. The integration of technology and successful clinical trials of drugs for treating critical ailments have boosted Wall Street’s optimism about several stocks in the sector. For instance, analysts expect Bionano (BNGO), Cerus (CERS), Agenus (AGEN), and VBI (VBIV) to gain by more than 60% in the near term. Read on.

Biotech ETFS: How To Pick Biotech Stock Winners And Avoid 2020 Volatility

Biotech ETFs allow investors to buy into a basket of biotech stocks, rather than trying to select specific winners. This eases up on volatility.